JP2024537137A - Kras g12d阻害剤とイリノテカンとの組み合わせ及び関連する治療方法 - Google Patents

Kras g12d阻害剤とイリノテカンとの組み合わせ及び関連する治療方法 Download PDF

Info

Publication number
JP2024537137A
JP2024537137A JP2024520703A JP2024520703A JP2024537137A JP 2024537137 A JP2024537137 A JP 2024537137A JP 2024520703 A JP2024520703 A JP 2024520703A JP 2024520703 A JP2024520703 A JP 2024520703A JP 2024537137 A JP2024537137 A JP 2024537137A
Authority
JP
Japan
Prior art keywords
kras
irinotecan
inhibitor
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537137A5 (cg-RX-API-DMAC7.html
Inventor
ハリン,ジル
クリステンセン,ジェームズ・ゲイル
ボウカット,ビッキー
オルソン,ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of JP2024537137A publication Critical patent/JP2024537137A/ja
Publication of JP2024537137A5 publication Critical patent/JP2024537137A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024520703A 2021-10-05 2022-10-04 Kras g12d阻害剤とイリノテカンとの組み合わせ及び関連する治療方法 Pending JP2024537137A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252405P 2021-10-05 2021-10-05
US63/252,405 2021-10-05
PCT/US2022/045625 WO2023059600A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with irinotecan and related methods of treatment

Publications (2)

Publication Number Publication Date
JP2024537137A true JP2024537137A (ja) 2024-10-10
JP2024537137A5 JP2024537137A5 (cg-RX-API-DMAC7.html) 2025-09-30

Family

ID=85803676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520703A Pending JP2024537137A (ja) 2021-10-05 2022-10-04 Kras g12d阻害剤とイリノテカンとの組み合わせ及び関連する治療方法

Country Status (10)

Country Link
US (1) US20250249003A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412720A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537137A (cg-RX-API-DMAC7.html)
KR (1) KR20240073115A (cg-RX-API-DMAC7.html)
CN (1) CN118354794A (cg-RX-API-DMAC7.html)
AU (1) AU2022361219A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233571A1 (cg-RX-API-DMAC7.html)
IL (1) IL311863A (cg-RX-API-DMAC7.html)
MX (1) MX2024004214A (cg-RX-API-DMAC7.html)
WO (1) WO2023059600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
IL311863A (en) 2024-06-01
EP4412720A4 (en) 2025-08-13
MX2024004214A (es) 2024-07-29
WO2023059600A1 (en) 2023-04-13
CA3233571A1 (en) 2023-04-13
CN118354794A (zh) 2024-07-16
KR20240073115A (ko) 2024-05-24
EP4412720A1 (en) 2024-08-14
US20250249003A1 (en) 2025-08-07
AU2022361219A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
JP7546549B2 (ja) 組み合わせ療法
JP2024537139A (ja) KRAS G12D阻害剤とPI3Ka阻害剤との組み合わせ及び関連する治療方法
JP2025000630A (ja) 組み合わせ療法
KR20240073115A (ko) 이리노테칸과 kras g12d 억제제의 조합 및 관련된 치료 방법
CN118382459A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
JP2024540839A (ja) Kras g12d阻害剤とshp-2阻害剤との併用療法
JP2025148403A (ja) 組み合わせ療法
JP2025000629A (ja) 組み合わせ療法
KR20210113587A (ko) 병용 요법
JP2024537136A (ja) KRAS G12D阻害剤と汎ErbBファミリー阻害剤との併用療法
JP2024521788A (ja) 併用療法
CN119031916A (zh) 包含sos1抑制剂和egfr抑制剂的组合疗法
WO2014177915A1 (en) Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
HK40108579A (en) Combinations of kras g12d inhibitors with irinotecan and related methods of treatment
JP2025513802A (ja) Sos1阻害剤及びmek阻害剤を含む併用療法
CN113840823B (zh) 显示癌细胞生长抑制效果的新型杂环取代的嘧啶衍生物,以及包含其的药物组合物
HK40108895A (en) Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment
TW202428280A (zh) 組合療法
HK40109896A (en) Combination therapies of kras g12d inhibitors with shp-2 inhibitors
HK40109895A (en) Combination therapies of kras g12d inhibitors with sos1 inhibitors
TW201808300A (zh) σ受體配體在癌症中的用途
HK40109894A (en) Combination therapies of kras g12d inhibitors with pan erbb family inhibitors
HK40101229A (zh) 组合疗法
HK40074319A (en) Combination therapies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250919